Distinguished in Neuroendocrine Tumor

Dr. Alexander Spira

Hematology | Oncology

Virginia Cancer Specialists, P.C

44035 Riverside Pkwy, Suite 300,

Leesburg, VA

Clinical Trials:Currently Recruiting for 3 Trials

Offers Telehealth

Distinguished in Neuroendocrine Tumor

Virginia Cancer Specialists, P.C

44035 Riverside Pkwy, Suite 300,

Leesburg, VA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alexander Spira is a Hematologist and an Oncologist in Leesburg, Virginia. Dr. Spira is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

His clinical research consists of co-authoring 160 peer reviewed articles and participating in 79 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 14 clinical trials in the study of Neuroendocrine Tumor.

Specialties

Hematology

Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Sentara Northern Virginia Medical Center

Reston Hospital Center

Virginia Hospital Center

Inova Fairfax Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

CareFirst

Cigna

First Health

INSURANCE PLAN
MEDICARE PDP
PPO

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

HealthKeepers

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Innovation Health

Kaiser Permanente

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER MEDICARE
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

Piedmont

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 14 Less Insurance Carriers -

Locations

VIRGINIA CANCER SPECIALISTS, P.C.
44035 Riverside Pkwy, Suite 300, Leesburg, VA 20176

Call: 703-554-6800

Additional Areas of Focus

Dr. Spira has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

76 Clinical Trials

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Enrollment Status: Recruiting

Publish Date: September 05, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors

Enrollment Status: Recruiting

Publish Date: May 29, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Enrollment Status: Recruiting

Publish Date: January 13, 2025

Intervention Type: Drug

Study Drug: INBRX-109

Study Phase: Phase 2

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy

Enrollment Status: Completed

Publish Date: September 25, 2025

Intervention Type: Drug

Study Drugs: Trilaciclib, Topotecan

Study Phase: Phase 1/Phase 2

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)

Enrollment Status: Completed

Publish Date: September 25, 2025

Intervention Type: Drug

Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab

Study Phase: Phase 2

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Drug

Study Drug: HBI-2376

Study Phase: Phase 1

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Enrollment Status: Completed

Publish Date: September 12, 2025

Intervention Type: Drug

Study Drugs: Brigatinib, Alectinib

Study Phase: Phase 3

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Drug

Study Drug: Entrectinib

Study Phase: Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: August 26, 2025

Intervention Type: Drug

Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant

Study Phase: Phase 2

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Enrollment Status: Completed

Publish Date: August 20, 2025

Intervention Type: Drug

Study Drug: STRO-002

Study Phase: Phase 1

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)

Enrollment Status: Active_not_recruiting

Publish Date: August 14, 2025

Intervention Type: Drug

Study Drug: Tepotinib

Study Phase: Phase 2

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Drug

Study Drugs: Tucatinib, Trastuzumab, Fulvestrant

Study Phase: Phase 2

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Drug

Study Drug: APG-115+Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: July 31, 2025

Intervention Type: Biological

Study Drugs: MGC018, MGA012

Study Phase: Phase 1/Phase 2

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: July 04, 2025

Intervention Type: Drug

Study Drugs: Itacitinib, Osimertinib

Study Phase: Phase 1/Phase 2

A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: July 03, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

Enrollment Status: Active_not_recruiting

Publish Date: June 04, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 1/Phase 2

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Enrollment Status: Active_not_recruiting

Publish Date: May 23, 2025

Intervention Type: Drug

Study Drugs: ONC-392, Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)

Enrollment Status: Active_not_recruiting

Publish Date: May 18, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: May 08, 2025

Intervention Type: Drug

Study Drug: Surufatinib+Tislelizumab

Study Phase: Phase 1/Phase 2

Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: April 09, 2025

Intervention Type: Drug

Study Drug: ASTX295

Study Phase: Phase 1

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

Enrollment Status: Terminated

Publish Date: April 03, 2025

Intervention Type: Drug

Study Drug: Seribantumab

Study Phase: Phase 2

Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)

Enrollment Status: Terminated

Publish Date: March 26, 2025

Intervention Type: Drug

Study Drug: Capmatinib

Study Phase: Phase 2

Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Enrollment Status: Terminated

Publish Date: March 17, 2025

Intervention Type: Drug

Study Drugs: SAR408701, Pembrolizumab, Cisplatin, Carboplatin

Study Phase: Phase 2

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Enrollment Status: Completed

Publish Date: March 17, 2025

Intervention Type: Drug

Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed

Study Phase: Phase 2

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies

Enrollment Status: Terminated

Publish Date: February 10, 2025

Intervention Type: Drug

Study Drugs: SEA-TGT, Pembrolizumab

Study Phase: Phase 1

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

Enrollment Status: Active_not_recruiting

Publish Date: February 04, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2025

Intervention Type: Drug

Study Drugs: VS-6766, Defactinib

Study Phase: Phase 2

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Enrollment Status: Completed

Publish Date: January 29, 2025

Intervention Type: Drug

Study Drug: ZW49

Study Phase: Phase 1

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Enrollment Status: Approved_for_marketing

Publish Date: January 17, 2025

Intervention Type: Drug

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer

Enrollment Status: Completed

Publish Date: December 09, 2024

Intervention Type: Drug

Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab

Study Phase: Phase 1

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Enrollment Status: Completed

Publish Date: November 19, 2024

Intervention Type: Biological, Other

Study Drugs: Galinpepimut-S, Pembrolizumab

Study Phase: Phase 1/Phase 2

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Enrollment Status: Terminated

Publish Date: October 23, 2024

Intervention Type: Drug

Study Drug: INBRX-105 PDL1x41BB Antibody

Study Phase: Phase 1

A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

Enrollment Status: Completed

Publish Date: October 10, 2024

Intervention Type: Drug

Study Drugs: Eniluracil, Capecitabine

Study Phase: Phase 1

A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Terminated

Publish Date: October 09, 2024

Intervention Type: Drug

Study Drug: Canakinumab

Study Phase: Phase 3

A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: August 09, 2024

Intervention Type: Drug

Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab

Study Phase: Phase 1

A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: July 24, 2024

Intervention Type: Drug

Study Drug: NBF-006

Study Phase: Phase 1

A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations

Enrollment Status: Terminated

Publish Date: June 13, 2024

Intervention Type: Drug

Study Drug: TPX-0046

Study Phase: Phase 1/Phase 2

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Enrollment Status: Completed

Publish Date: June 11, 2024

Intervention Type: Drug

Study Drug: STRO-001

Study Phase: Phase 1

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: June 04, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Enrollment Status: Terminated

Publish Date: June 04, 2024

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: June 04, 2024

Intervention Type: Drug

Study Drugs: ADXS-503, Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

Enrollment Status: Active_not_recruiting

Publish Date: June 03, 2024

Intervention Type: Drug

Study Drug: Nab-sirolimus

Study Phase: Phase 2

A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia

Enrollment Status: Completed

Publish Date: May 03, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Enrollment Status: Completed

Publish Date: May 03, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent

Enrollment Status: Terminated

Publish Date: April 18, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

Enrollment Status: Terminated

Publish Date: April 02, 2024

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors

Enrollment Status: Completed

Publish Date: March 27, 2024

Intervention Type: Drug, Radiation

Study Phase: Phase 1/Phase 2

A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Enrollment Status: Completed

Publish Date: March 20, 2024

Intervention Type: Drug

Study Drug: INC280

Study Phase: Phase 2

An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy

Enrollment Status: Completed

Publish Date: February 05, 2024

Intervention Type: Drug

Study Drugs: Ramucirumab, Necitumumab, Osimertinib

Study Phase: Phase 1

View 47 Less Clinical Trials

160 Total Publications

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.

Journal: The New England journal of medicine

Published: September 09, 2025

View All 160 Publications

Similar Doctors

Elite in Neuroendocrine Tumor

Dr. Ana C. De Jesus Acosta

Oncology

Elite in Neuroendocrine Tumor

Dr. Ana C. De Jesus Acosta

Oncology

Johns Hopkins University

600 N Wolf St,

Baltimore, MD

(49.9 miles away)

410-955-5000

Languages Spoken:

English, Spanish

See accepted insurances

Accepting New Patients

Offers Telehealth

Ana De Jesus Acosta is an Oncologist in Baltimore, Maryland. Dr. De Jesus Acosta is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. De Jesus Acosta is currently accepting new patients.

Distinguished in Neuroendocrine Tumor

Dr. Sandy D. Kotiah

Oncology | Hematology

Distinguished in Neuroendocrine Tumor

Dr. Sandy D. Kotiah

Oncology | Hematology

Lutherville Hematology And Oncology Services

7602 Belair Rd,

Baltimore, MD

(55.2 miles away)

410-494-9099

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Sandy Kotiah is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Kotiah is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Neuroendocrine Tumor, Paget Disease of the Breast, Anemia, Lynch Syndrome, and Bone Marrow Aspiration. Dr. Kotiah is currently accepting new patients.

Distinguished in Neuroendocrine Tumor

Dr. Daniel A. Laheru

Oncology

Distinguished in Neuroendocrine Tumor

Dr. Daniel A. Laheru

Oncology

Johns Hopkins University

600 N Wolf St,

Baltimore, MD

(49.9 miles away)

410-955-5000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Daniel Laheru is an Oncologist in Baltimore, Maryland. Dr. Laheru is rated as an Elite provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Laheru is currently accepting new patients.

VIEW MORE NEUROENDOCRINE TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spira's expertise for a condition

ConditionClose